V Wee yong lab calgary


Neuroimmunology is the study of inflammation in the nervous system. Virtually all neurological disorders
have inflammatory components, and these include diseases traditionally associated with overt inflammation,
such as multiple sclerosis (MS), and those previously thought to be purely degenerative, including Alzheimer's
disease. Neuroinflammation originates from the trafficking of several leukocyte subsets into the nervous system
and through the production of immune molecules by neural cells themselves. The interaction between leukocytes
and neural cells further promotes neuroinflammation and injury. In recent years, reparative properties of
neuroinflammation have been appreciated, so that the balance between beneficial and detrimental neuroinflammation
is a crucial determinant of outcome. My research projects have been guided by 3 diseases of the central nervous
system (CNS): MS, spinal cord injury (SCI) and brain tumors (malignant gliomas). MS and SCI provide my research
program with diseases of chronic and acute neuroinflammation, respectively. In contrast, malignant gliomas present
a disease of immunosuppression, whereby the cancer cells neutralize the activity of leukocytes that infiltrate into these
tumors. Collectively, my studies of these 3 diseases are aimed at understanding, controlling and tipping the balance of
neuroinflammation towards one of neuroprotection and regeneration from CNS insults.


1. Canadian Institutes for Health Research, Defining EMMPRIN as a key regulator of neuroinflammation and neural injury in multiple sclerosis, 2014 - 2019,$184,150 per annum

2. Multiple Sclerosis Society of Canada, Chondroitin sulfate proteoglycans (CSPGs) as inhibitors of remyelination in MS, 2013 - 2016,$100,000 per annum

3. Multiple Sclerosis Society of Canada Foundation Grant, on: A phase III double-blind, randomized, placebo-controlled trial of minocycline in clinically isolated syndromes (CIS), July 2007- ongoing (PI: L. Metz, involving 15 MS centers across Canada; scientific leader: Yong).$4.1 million total. **

4. Multiple Sclerosis Society of Canada Foundation Grant, on: Pathobiology of MS: complex interplay between degeneration and inflammation, PI: Peter Stys.My portion is $175,000 per year, 2011 – 2014

5.Alberta/Pfizer Translational Research Fund Opportunity, on: N-acetylglucosamine analogs that promote remyelination and reduce detrimental inflammation: Novel therapeutics for multiple benefits in multiple sclerosis (PI: Yong, Co-PI: CC Ling).$200,000 for 18 months, 2014 – 2016

6. Alberta Innovates – Health Solutions/Alberta Cancer Foundation,
Activating microglia and macrophages to suppress brain tumor-initiating cells (PI: Yong, Co-PIs: J Dunn and J Kelly).$250,000/year, 2014 – 2017

7. Alberta Innovates – Health Solutions CRIO Team grant, Medicines for Remyelination in Multiple Sclerosis: The Next Frontier (PI: Yong, Co-PI: L Metz, with C Power, CC Ling, G Metz, B Pike, Y Zhang, J Dunn, P Stys, MKoch, D Broadhurst).$1 million/year, 2014 - 2019

8.Industry grants are not listed